Predictive Factors for Complete Myoma Resection During Hysteroscopic Myomectomy

Sponsor
Ospedale Policlinico San Martino (Other)
Overall Status
Recruiting
CT.gov ID
NCT04400942
Collaborator
(none)
600
1
83
7.2

Study Details

Study Description

Brief Summary

The aim of this observational retrospective analysis is to evaluate predictive factors for complete myoma resection during hysteroscopic myomectomy for developing and validating a nomogram.

This tool can help clinicians to support the patient in making an informed decision about therapeutic options for uterine submucous myomas by defining risk factors predicting a high complexity myomectomy.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Transvaginal ultrasound
  • Behavioral: Anamnesis
  • Procedure: Operative hysteroscopy

Detailed Description

Overall, 10% of all uterine myomas are submucosal. These myomas spread into the uterine cavity, lifting the endometrial mucosa, and are a common cause of abnormal uterine bleeding, dysmenorrhea, early miscarriage and they may be a cause of infertility.

Hysteroscopic myomectomy is the surgical procedure of choice for the treatment of submucosal myomas, because it is minimally invasive and has the advantage of preserving the integrity of the uterine wall.

The characteristics of the myomas (size, number and location) enables the surgeon to choose the surgical approach that will provide the best outcome for the patient, and may predict the chances of a complete hysteroscopic resection of myomas in one procedure.

Study Design

Study Type:
Observational
Anticipated Enrollment :
600 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
A Retrospective Study for Developing a Nomogram for Predicting Change of Complete Myoma Resection During Hysteroscopic Myomectomy
Actual Study Start Date :
Jan 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Women with uterine myomas undergoing hysteroscopic myomectomy

Diagnostic Test: Transvaginal ultrasound
Transvaginal ultrasonographic scan aims to evaluate number, size (diameter and volume), location and appearance of submucous uterine myomas, concomitant presence of adenomyosis

Behavioral: Anamnesis
Anamnesis aims to collect data about age, BMI, previous hormonal therapies (such as ulipristal acetate or gonadotropin-releasing hormone agonists) with submucous uterine myomas

Procedure: Operative hysteroscopy
Operative hysteroscopy allows a direct evaluation of number, size (diameter and volume), location and appearance of submucous uterine myomas. This exam allows the resection of the myomas.

Outcome Measures

Primary Outcome Measures

  1. Number of patients with complete resection of myomas [At the end of the hysteroscopic procedure]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Inclusion Criteria:
  • patients with ultrasonographic diagnosis of uterine myomas
Exclusion Criteria:
  • patients with previous incomplete hysteroscopic myoma resection;

  • patients undergoing additional surgical procedures performed by hysteroscopy (such as, resection of endometrial polyps);

  • patients undergoing associated non-hysteroscopic surgical procedures;

  • patients with severe cardiovascular disease, decompensated diabetes and severe hematologic disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS Ospedale Policlinico San Martino Genoa Italy 16132

Sponsors and Collaborators

  • Ospedale Policlinico San Martino

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fabio Barra, Principal Investigator, Ospedale Policlinico San Martino
ClinicalTrials.gov Identifier:
NCT04400942
Other Study ID Numbers:
  • NOM-MYOMA RES
First Posted:
May 26, 2020
Last Update Posted:
Mar 4, 2021
Last Verified:
Mar 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 4, 2021